REFILE-UPDATE 1-Novavax delays U.S. trial start of COVID-19 vaccine to November

(Refiled for dropped numeral in headline)

Oct 27 (Reuters) - Novavax Inc on Tuesday delayed the timeline for beginning a late-stage U.S. trial of its experimental coronavirus vaccine by roughly one month.

The company said it would begin the trial by the end of November. It previously expected to start this month.

Novavax said it also expects interim data from an ongoing late-stage UK trial of its coronavirus vaccine in the first quarter of next year.

The company said it had expanded its enrollment target in the UK trial to 15,000 volunteers from 10,000. It expects this could help assess safety and effectiveness of the vaccine in a shorter time period. (Reporting by Manas Mishra in Bengaluru; Editing by Shailesh Kuber, Bernard Orr)


Reuters Breakingviews is the world's leading source of agenda-setting financial insight. As the Reuters brand for financial commentary, we dissect the big business and economic stories as they break around the world every day. A global team of about 30 correspondents in New York, London, Hong Kong and other major cities provides expert analysis in real time.

Sign up for a free trial of our full service at and follow us on Twitter @Breakingviews and at All opinions expressed are those of the authors.